The specter of generic competition has long loomed around copyright’s iconic drug, Viagra, sparking questions about the outlook of similar pharmaceutical holdings. While first periods saw impressive gains, the exclusivity expiration has allowed the way for less expensive copies, potentially diminishing earnings and creating a genuine risk for inv